Evidence map›Paper›PMID 40126859›Full record

ArticleCEN case reports2025

Tubular damage and SGLT2 expression in a patient with Beni-koji tablet-associated acute kidney injury and Fanconi syndrome.

Ayaka Kamada, Takuo Hirose, Hideaki Hashimoto, Yukari Konya, Fumiya Sato, Katsuya Ishiyama, Kensuke Joh, Wako Yumura, Takefumi Mori

Abstract readCase Reports
In one paragraph

Article in CEN case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ayaka KamadaDivision of Nephrology and Endocrinology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 1-15-1, Fukumuro, Miyagino, Sendai, 983-8536, Japan.
Takuo HiroseDivision of Nephrology and Endocrinology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 1-15-1, Fukumuro, Miyagino, Sendai, 983-8536, Japan. hirose.takuo@tohoku-mpu.ac.jp.ORCID 0000-0002-8761-3779
Hideaki HashimotoDivision of Nephrology and Endocrinology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 1-15-1, Fukumuro, Miyagino, Sendai, 983-8536, Japan.
Yukari KonyaDivision of Nephrology and Endocrinology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 1-15-1, Fukumuro, Miyagino, Sendai, 983-8536, Japan.
Fumiya SatoDivision of Nephrology and Endocrinology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 1-15-1, Fukumuro, Miyagino, Sendai, 983-8536, Japan.
Katsuya IshiyamaDivision of Nephrology and Endocrinology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 1-15-1, Fukumuro, Miyagino, Sendai, 983-8536, Japan.
Kensuke JohDepartment of Pathology, The Jikei University School of Medicine, Tokyo, Japan.
Wako YumuraDivision of Nephrology and Endocrinology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 1-15-1, Fukumuro, Miyagino, Sendai, 983-8536, Japan.
Takefumi MoriDivision of Nephrology and Endocrinology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 1-15-1, Fukumuro, Miyagino, Sendai, 983-8536, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since March 2024, many cases of renal dysfunction have been reported in Japan among individuals taking a supplement containing red yeast rice. We present the case of a 51-year-old woman who developed renal dysfunction and Fanconi syndrome after taking the supplement. The patient was referred to our hospital with hypouricemia, hypokalemia, hypophosphatemia, and glucosuria. Following a renal biopsy broadcast reports of kidney damage caused by the red yeast rice supplement and the patient's declaration of taking this supplement, we diagnosed her with supplement-induced acute kidney injury and Fanconi syndrome. Renal pathological findings revealed acute tubular necrosis, including brush border loss and mitochondrial fragmentation in the proximal tubular cells. These were consistent with the clinical and pathological findings of previous cases involving the red yeast rice supplement. Additionally, a reduction in sodium-glucose co-transporter 2 (SGLT2) expression was observed in the proximal tubules, supporting that the red yeast rice supplement damaged the proximal tubular cells. The reduction of SGLT2 protein expression may be linked to supplement-induced glucosuria. After supplement intake was ceased, renal function recovered and laboratory findings including glucosuria returned to normal within 6 months. The loss of glucosuria suggests that SGLT2 protein expression may be reversible. In consideration of our case and previous cases, it is probable that the nephrotoxicity of red yeast rice supplement is primarily affecting the proximal tubules, particularly the S1 and S2 segments.

Indexed as

Acute Kidney InjuryBiological ProductsDietary SupplementsFanconi SyndromeSodium-Glucose Transporter 2FemaleGlycosuriaHumansJapanKidney Tubules, ProximalMiddle AgedTabletsBiological Productsred yeast riceSLC5A2 protein, humanSodium-Glucose Transporter 2TabletsAcute tubular necrosisFanconi syndromeRed yeast rice supplementSGLT2

Identifiers

PMID40126859
PMCPMC12126451

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.